Floatz logo

Pyrotinib

Extranodal NK/T-cell Lymphoma

Rong TaoSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Extranodal NK/T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BB
Tucidinostat
Ruijin Hospital
Phase 4BB
Eloxatin
CStone Pharmaceuticals
Phase 3BB
Sugemalimab
CStone Pharmaceuticals
Phase 3B
Tislelizumab
Rong Tao
Phase 2B

View all 13 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →